These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 29308539)

  • 21. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
    Hempe JM; Liu S; Myers L; McCarter RJ; Buse JB; Fonseca V
    Diabetes Care; 2015 Jun; 38(6):1067-74. PubMed ID: 25887355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.
    Blomster JI; Zoungas S; Chalmers J; Li Q; Chow CK; Woodward M; Mancia G; Poulter N; Williams B; Harrap S; Neal B; Patel A; Hillis GS
    Diabetes Care; 2014; 37(5):1353-9. PubMed ID: 24578358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of Peripheral Pulses and Risk of Major Vascular Outcomes in Patients With Type 2 Diabetes.
    Mohammedi K; Woodward M; Zoungas S; Li Q; Harrap S; Patel A; Marre M; Chalmers J;
    Diabetes Care; 2016 Dec; 39(12):2270-2277. PubMed ID: 27679583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
    Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
    Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE.
    Klein KR; Franek E; Marso S; Pieber TR; Pratley RE; Gowda A; Kvist K; Buse JB
    BMJ Open Diabetes Res Care; 2021 Nov; 9(2):. PubMed ID: 34819298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
    ADVANCE Management Committee
    Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
    Mohammedi K; Woodward M; Hirakawa Y; Zoungas S; Williams B; Lisheng L; Rodgers A; Mancia G; Neal B; Harrap S; Marre M; Chalmers J;
    Diabetes Care; 2016 Oct; 39(10):1796-803. PubMed ID: 27456835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between the haemoglobin glycation index (HGI) and clinical outcomes in patients with acute decompensated heart failure.
    Cheng W; Huang R; Pu Y; Li T; Bao X; Chen J; Li G; Wu H; Wei Z
    Ann Med; 2024 Dec; 56(1):2330615. PubMed ID: 38513606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
    Wong MG; Perkovic V; Chalmers J; Woodward M; Li Q; Cooper ME; Hamet P; Harrap S; Heller S; MacMahon S; Mancia G; Marre M; Matthews D; Neal B; Poulter N; Rodgers A; Williams B; Zoungas S;
    Diabetes Care; 2016 May; 39(5):694-700. PubMed ID: 27006512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.
    Woodward M; Hirakawa Y; Kengne AP; Matthews DR; Zoungas S; Patel A; Poulter N; Grobbee R; Cooper M; Jardine M; Chalmers J;
    Diabetes Obes Metab; 2016 Mar; 18(3):289-94. PubMed ID: 26661693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
    Poulter NR
    J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
    Beulens JW; Patel A; Vingerling JR; Cruickshank JK; Hughes AD; Stanton A; Lu J; McG Thom SA; Grobbee DE; Stolk RP; ;
    Diabetologia; 2009 Oct; 52(10):2027-36. PubMed ID: 19633827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study.
    Kim MK; Jeong JS; Yun JS; Kwon HS; Baek KH; Song KH; Ahn YB; Ko SH
    J Diabetes Complications; 2018 Oct; 32(10):906-910. PubMed ID: 30121206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial.
    Woodward M; Patel A; Zoungas S; Liu L; Pan C; Poulter N; Januszewicz A; Tandon N; Joshi P; Heller S; Neal B; Chalmers J
    Diabetes Care; 2011 Dec; 34(12):2491-5. PubMed ID: 21972410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Importance of blood pressure lowering in type 2 diabetes: focus on ADVANCE.
    Chalmers J; Arima H
    J Cardiovasc Pharmacol; 2010 Apr; 55(4):340-7. PubMed ID: 20422738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes.
    Lévy BI; Taddei S
    Curr Med Res Opin; 2018 Sep; 34(9):1557-1570. PubMed ID: 29307229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus.
    Waeber B; de la Sierra A; Ruilope LM
    Am J Cardiovasc Drugs; 2009; 9(5):283-91. PubMed ID: 19791837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited benefit of haemoglobin glycation index as risk factor for cardiovascular disease in type 2 diabetes patients.
    Østergaard HB; Mandrup-Poulsen T; Berkelmans GFN; van der Graaf Y; Visseren FLJ; Westerink J;
    Diabetes Metab; 2019 Jun; 45(3):254-260. PubMed ID: 29784563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advanced credit: patient enrolling and therapy initiation in the ADVANCE trial].
    Nagy V
    Orv Hetil; 2007 Sep; 148(39):1839-42. PubMed ID: 17890171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.